NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up ...

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...

Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the ...

Roche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that ...

Roche secures CE Mark approval for its automated mass spectrometry antibiotic monitoring reagents, expanding clinical ...

Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in its ...

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the rumour ...

Swiss pharmaceuticals company Roche agreed to acquire U.S.-based weight-loss drugmaker Carmot Therapeutics, which develops anti-obesity and diabetes drugs, for $2.7 billion, according to a press ...